SeaStar Medical (NASDAQ:ICU) rose 7.10% on June 23, 2026, as technical rebound lifted the blood-purification developer, with shares closing at $3.47.
Key Highlights
- Rose 7.10%: SeaStar Medical closed at $3.47 on June 23 after moving $0.23 per share.
- Catalyst: During the session, technical rebound lifted the blood-purification developer.
- Company: SeaStar Medical develops extracorporeal blood purification devices for acute organ failure.
- Session: The stock finished at $3.47, while the available company record showed a disclosed catalyst for the move.
SeaStar Medical (NASDAQ:ICU) rose 7.10% on June 23, 2026, closing at $3.47 after a $0.23 per-share move. The session’s advance came as technical rebound lifted the blood-purification developer, based on the available company disclosures and trading context.
No material announcement was identified. The medical device micro-cap developing extracorporeal blood purification therapies for acute organ failure recorded a technical rebound on low volume.
SeaStar Medical develops extracorporeal blood purification devices for acute organ failure.
SeaStar's SCD (Selective Cytopheretic Device) has received Breakthrough Device designation from the FDA. The modest session gain appeared to reflect routine trading noise rather than any specific catalyst.
The update concerned the development or regulatory path of a healthcare programme rather than a completed commercial launch. Clinical-stage milestones can include agency feedback, trial design, patient data or filing plans, each of which carries a different level of regulatory significance.
The shares closed at $3.47 after the market incorporated the disclosed programme information. The available record showed no additional approval decision during the June 23 session unless specifically stated in the company update.
The company’s own disclosures remain the primary record for separating a verified business event from a price move caused by market positioning. For June 23, the closing data and the stated catalyst provide the clearest account of the session without implying an unannounced change in fundamentals.
For the June 23 close, the defining facts were the 7.10% advance, the $3.47 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.


_11_18_2026_14_40_45_405856.jpg)



Please wait processing your request...